California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.


CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”


U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.


Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.


December 4, 2019

There was nothing particularly surprising in the Bank of Canada’s policy rate announcement this morning: The Bank of Canada today maintained its target for the overnight rate at 1 ¾ percent. The Bank Rate is correspondingly 2 percent and the deposit rate is 1 ½ percent. The ...

Plus Products still has big upside, PI says

Third quarter sales from Plus Products (Plus Products Stock Quote, Chart, News CSE:PLUS) were a disappointment but with one of its key competitors in the California cannabis edibles market now on the mat, look for PLUS to come out swinging in the next quarter, says PI Financial ...

Beacon slashes target on Indus Holdings, maintains “Buy”

US cannabis company Indus Holdings (Indus Holdings Stock Quote, Chart, News CSE:INDS) has got a lot to prove, says analyst Doug Cooper of Beacon Securities, who reviewed Indus’ latest quarterly results in an update to clients on Monday. Cooper says the stock is still a “Buy,...

2020 outlook: An optimistic view of capital markets

Welcome to December – just one more month until a new year begins (and, depending on how you do the math, a new decade as well). Naturally, this is the time when market-watchers issue their forecasts for what may lie ahead, and my team is no exception. Simply put, we expect co...

Is now the right time to invest in weed?

If there’s one group of people who can’t wait for 2019 to end, it’s cannabis investors. The ride they’ve been taken on over the last 12 months has been as nausea-inducing as any Canada Wonderland roller coaster, with stocks plummeting post-legalization in October 2018, r...

Thoughtful giving: 6 generous gift ideas that aren’t things

If you’ve ever visited a mall in the days leading up to December 25th, you know how intense the holiday shopping season can be.  One third of all Canadians say the holiday season is more stressful now than it was five years ago—the main reasons being overcrowded stores, pri...

Global real estate: A generally positive outlook, but balancing growth opportunities with risk mitigation is key

Economic growth has begun to moderate worldwide, as expected, but remains adequate to support real estate demand. Heading into 2020, real estate appears more attractively priced relative to other asset classes than it did in early 2019 amidst even lower long-term government bond...

Saving vs. investing: which is right for me

When should you save, and when should you invest? The answer depends on what you have planned for the future—and what you want to do with your money.  First, let’s look at the most important differences between saving and investing. Then, we’ll help you figure out which i...

“THC Kiss” submitted to Health Canada for approval

VANCOUVER, Nov. 20, 2019 /CNW/ – THC BioMed Intl Ltd. (CSE:THC) (“THC BioMed” or the “Company“) is excited to announce that it has submitted its cannabis beverage, THC KISS, for approval under the Cannabis Act as a new product by Health Canada. After the approval, i...

U.S. House Judiciary Committee approves bill to end cannabis prohibition

The historic vote marks the first time the committee has approved comprehensive legislation to remove cannabis from the schedule of controlled substances and address harms caused by prohibition. In a 24-10 vote, this morning, the U.S. House Judiciary Committee approved a bill th...